Erasca, Inc. announced updated preliminary Phase 1 data for its pan-RAS molecular glue ERAS-0015 from the AURORAS-1 trial, showing a 57% uORR 8wk in KRAS G12X pancreatic ductal adenocarcinoma patients at a 32 mg QD dose. The company plans to initiate potentially registration-enabling trials in non-small-cell lung cancer in the first half of 2027 and Phase 3 pivotal trials in pancreatic ductal adenocarcinoma and RAS-mutant NSCLC in 2027 or 2028. Erasca, Inc. is a biotechnology company focused on the discovery and development of product candidates that shut down the RAS/MAPK pathway.
